Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

Table 3

Platelet inhibition and anticoagulation (n = 991).

Indication for cangrelor
No pretreatment with oral P2Y12 inhibitor	950 (95.9%)
Pretreatment with oral P2Y12 inhibitor deemed insufficient	20 (2.0%)
Thrombus evolves during PCI without pretreatment with oral P2Y12 inhibitor	8 (0.8%)
Thrombus evolves during PCI despite pretreatment with oral P2Y12 inhibitor	7 (0.7%)
Uncertainty about bleeding and need for P2Y12 inhibition	6 (0.6%)
Aspirin prior to PCI	949 (95.8%)
Warfarin prior to PCI	17 (1.7%)
NOAC prior to PCI	27 (2.7%)
Oral P2Y12 inhibitor after PCI
No	15 (1.5%)
Clopidogrel	95 (9.6%)
Ticagrelor	881 (88.9%)
Unfractionated heparin as adjunct to PCI	974 (98.3%)
Abciximab as adjunct to PCI	21 (2.1%)
Bivalirudin as adjunct to PCI	2 (0.2%)
Eptifibatide as adjunct to PCI	1 (0.1%)

PCI: percutaneous coronary intervention; NOAC: novel oral anticoagulants.